New research presented at the European Association of Urology congress in Barcelona at the weekend suggests testosterone replacement therapy (TRT) may delay biochemical recurrence (BCR) in low-risk prostate cancer patients.
The study included 850 patients who underwent robot-assisted radical prostatectomy as primary treatment of localised prostate cancer between December 2009 and June 2018. Of these, 152 were treated with TRT to improve sexual function.
Data on prostate specific antigen (PSA), grade and stage were prospectively collected. BCR was defined as two consecutive PSA values of 0.2 ng/dL or greater.
After a median follow-up of 2.75 years, 9.9 per cent of patients on TRT developed BCR compared with 23.5 per cent patients in the group not on TRT (P<.001 authors noted that in all patients who experienced bcr those receiving had a median longer latency of disease progression.>
“We’re not suggesting that treatment methods be changed just yet, but this puts us at the stage where we need to question the taboo against testosterone use in prostate cancer therapy - especially for low-risk patients after radical prostatectomy,” said author Professor Thomas Ahlering from the University of California, USA.